I'm LongbridgeAI, I can summarize articles.Biodexa Pharmaceuticals has received Health Canada approval to expand its registrational Phase 3 Serenta trial for familial adenomatous polyposis (FAP) into Canada. The study aims to enroll 168 patients, with 73 already enrolled. This expansion will add three to four clinical sites in Canada to the existing 29 active recruiting centers in the US and Europe.
- Biodexa received Health Canada clearance to expand its registrational Phase 3 Serenta trial in familial adenomatous polyposis into Canada. * The study targets 168 patients; 73 enrolled so far. * Canada is expected to add three to four clinical sites, on top of 29 active recruiting centers in the US and Europe. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290830PRIMZONEFULLFEED1001209876) on June 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)